The German contract research firm Evotec has formed two drug discovery agreements with Sanofi. In the first, Evotec and Apeiron Biologics are joining with Sanofi to develop small-molecule-based cancer immunotherapies. Evotec and Apeiron will get undisclosed research payments and could reap milestone payments of more than $200 million. In the second, Evotec and Sanofi will combine their know-how in human β cells to identify β-cell-active small molecules and biologics that could treat diabetes. Evotec will get $3 million up front plus milestones.